Skip to content

Microsurfaced Grafts in Deep Burn Wounds

A Prospective, Randomized Study to Evaluate the Effectiveness of Microsurfaced vs Control Cadaveric Decellularized Grafts to Establish Wound Bed Preparedness in Deep Partial and Full Thickness Burn Wounds

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04589442
Enrollment
20
Registered
2020-10-19
Start date
2021-01-04
Completion date
2021-12-31
Last updated
2021-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns, Wound Heal

Brief summary

This study is designed as a prospective, randomized, within subject controlled design to evaluate the effectiveness of Microsurfaced vs Control cadaveric grafts for coverage of acute deep-partial or full-thickness burn wounds to promote wound healing. This study will be performed in 2 parts: Time to wound bed preparedness through 6 weeks (Part A) and wound site healing, graft take and long-term scar outcomes (Part B). Subjects will be treated with both control and microsurfaced cadaveric grafts on adjacent deep-partial or full-thickness burn wounds.

Interventions

standard of care graft

BIOLOGICALmicrosurfaced split thickness skin graft

standard of care graft that has been microsurfaced

Sponsors

CellTherX
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent by patient or Legally Authorized Representative (LAR) * Subject with deep partial or full thickness burn injury due to flame burn, scald injury or contact burn * Study burn site large enough to accommodate placement of control and microsurfaced cadaveric graft (minimum 4 cm2 each) at the same location OR 2 study burn sites large enough to each accommodate control and microsurfaced cadaveric graft, respectively at minimum 4 cm2. * Total Body Surface Area burned (TBSA) total ≤30 % * Admission within 72 hours of burn injury * Non-infected wound as diagnosed by the attending physician upon admission * Treated as an outpatient or in an observational setting * 21 years of age or older

Exclusion criteria

* Burns involving the face * Causes other than contact burn, flame or scald injuries (i.e., electrical, chemical or frostbite) * Admission time greater than 72 hours after the injury * Wounds noted to be infected at admission * Is pregnant or plans to become pregnant * Is nursing or actively lactating * Developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including untreated schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years. * Active alcohol or substance abuse in the opinion of the investigator that could impair the subject's participation in the study protocol or record study materials * Any medical condition or co-morbidity that in the opinion of the investigator, would prevent successful participation in the study

Design outcomes

Primary

MeasureTime frameDescription
Wound bed prep6 weekTo compare wound bed preparedness/time to autograft in deep-partial and full thickness burns and burn wound healing in partial thickness burns in burn sites treated with Microsurfaced vs Control cadaveric graft-treated groups through 6 weeks post initial injury.

Secondary

MeasureTime frameDescription
Tissue Oxygenation6 weeksChange in tissue oxygenation at study burn site at the time of autografting as compared to baseline.
InfectionThrough 12 monthsIncidence of Infection at each treatment study visit
Autograft take2 weeksAutograft take will be documented as a percentage of the graft by the physician
Tissue oxygenation2 weeksTissue oxygenation will be assessed using hyperspectral imaging
Scar assessment3, 6, 9, 12 monthsScar will be assessed using the Patient and Observer Scar Assessment Scale (POSAS)

Countries

United States

Contacts

Primary ContactJoan Wilson
joan.wilson@jmsreserachfoundation.org706-364-2966

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026